PetMeds reports preliminary Q4 sales decline, delays annual filing

PetMed Express (PETS) announced it will delay filing its fiscal year 2025 annual report and released preliminary Q4 results, projecting a net loss between $9.9 million and $10.4 million compared to a $5.0 million loss in the prior year quarter, with sales declining from $66.5 million to between $51.1 million and $53.1 million; full year sales are expected to decline from $281.1 million to between $231.6 million and $233.6 million. Despite these challenges, the company reported $54.7 million in cash and no debt as of March 31, 2025, and maintains a "Fair" overall financial health score according to InvestingPro analysis, with strengths in cash flow and relative value.

Analysis

PetMed Express (PETS) is navigating significant operational headwinds, as indicated by its preliminary fourth-quarter results showing an anticipated sales decline to between $51.1 million and $53.1 million, a sharp decrease from $66.5 million in the prior-year period, and contributing to a near 11% revenue decline over the last twelve months. This downturn is projected to widen the quarterly net loss to between $9.9 million and $10.4 million, compared to a $5.0 million loss previously. While the full fiscal year 2025 net loss is estimated to narrow to between $4.5 million and $5.0 million from $7.5 million in fiscal 2024, this improvement is substantially aided by an $8.7 million one-time non-cash stock compensation reversal, offset by a $6.4 million tax expense from a valuation allowance. The company's decision to delay its Form 10-K filing until a target date of July 1, 2025, introduces an element of uncertainty. Despite these challenges and its stock trading near a 52-week low, PETS reported a solid balance sheet with $54.7 million in cash and no debt as of March 31, 2025. InvestingPro data suggests a "Fair" overall financial health score, with notable strengths in cash flow and relative value metrics. Strategic moves, including a partnership with telemedicine provider Dutch and the appointment of Peter Batushansky to the board, reflect ongoing efforts to transform the business amidst increasing competition, a concern also flagged by Morgan Stanley which recently lowered its price target on PETS to $3.20 while maintaining an Underweight rating.

Key Decisions for Investors

• Investors should closely scrutinize the delayed Form 10-K for detailed financial disclosures and management's explanation for the significant Q4 sales contraction and widening net loss.
• The company's robust cash position and lack of debt provide a financial cushion, but the effectiveness of strategic initiatives, such as the Dutch partnership and new board expertise, in addressing competitive pressures and reversing negative sales trends remains a key watchpoint.
• With the stock trading near its 52-week low and facing analyst downgrades, a cautious approach is advised, focusing on the tangible outcomes of turnaround efforts and improved operational metrics before committing further capital.